HRP20220339T1 - Antibakterijski spojevi - Google Patents
Antibakterijski spojevi Download PDFInfo
- Publication number
- HRP20220339T1 HRP20220339T1 HRP20220339TT HRP20220339T HRP20220339T1 HR P20220339 T1 HRP20220339 T1 HR P20220339T1 HR P20220339T T HRP20220339T T HR P20220339TT HR P20220339 T HRP20220339 T HR P20220339T HR P20220339 T1 HRP20220339 T1 HR P20220339T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- ring
- optionally substituted
- compound
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 28
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000008827 tuberculosis Diseases 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 229940121383 antituberculosis agent Drugs 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 239000000814 tuberculostatic agent Substances 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (20)
1. Spoj s formulom (IA) za upotrebu u liječenju tuberkuloze
[image]
naznačen time što
R1 predstavlja vodik;
L1 predstavlja -CH2-;
X1 predstavlja po izboru fenilensku ili naftilensku aromatsku poveznu skupinu (koja povezna skupina može sama po sebi biti po izboru supstituirana s jednim ili više supstituenata odabranih između fluora, -OH, -OC1-6 alkila i C1-6 alkila, pri čemu su posljednja dva alkilna ostatka sami po izboru supstituirani s jednim ili više fluoro atoma);
Xa predstavlja C(H) ili N;
Xb predstavlja C(H), N, O (u kojem slučaju L2 nije prisutan) ili C=O (u kojem slučaju L2 također nije prisutan);
q1 predstavlja -CH2-, -CH2-CH2-, -O-CH2- ili "-";
q2 predstavlja -CH2- ili -CH2-CH2-;
q3 predstavlja -CH2- ili -CH2-CH2-;
q4 predstavlja -CH2- ili -CH2-CH2-;
kada Xb predstavlja O ili C=O, tada L2 nije prisutan;
kada Xb predstavlja C(H) ili N, tada L2 može predstavljati vodik, halo, -ORf, -C(O)-Rg, C1-6 alkil (po izboru supstituiran s jednim ili više halo, npr. atomima fluora) ili aromatsku skupinu (po izboru supstituiranu s jednim ili više supstituenata odabranih od halo, C1-6 alkila (sam je po izboru supstituiran s jednim ili više supstituenata odabranih od fluoro, -CF3 i/ili -SF5), -OC1-6alkila (sam je po izboru supstituiran s jednim ili više fluoro atoma),-O-fenila (sam je po izboru supstituiran s halo, C1-6alkil, C1-6fluoroalkil i/ili -OC1-6alkil) ili -SF5); ili, kada je vezan na dušik, tj. kada Xb je N, L2 predstavlja -S(O)2-C1-6alkil po izboru supstituiran s jednim ili više fluoro atoma;
Rf predstavlja vodik, C1-6 alkil (po izboru supstituiran s jednim ili više fluora) ili aromatsku skupinu (sama je po izboru supstituirana s jednim ili više supstituenata odabranih od halo, C1-6alkila i -OC1-6alkila, pri čemu posljednja dva alkilna ostatka mogu sami po izboru mogu biti supstituirani s jednim ili više fluoro atoma);
Rg predstavlja vodik ili C1-6alkil (po izboru supstituiran s jednim ili više supstituenata odabranih od fluora, ili -OC1-3 alkila, koji je potonji dio također izborno supstituiran s jednim ili više fluoro atoma) ili aromatsku skupinu (po izboru supstituiranu s jednim ili više supstituenata odabranih od halo, C1-6 alkila ili -OC1-6alkila);
prsten A može biti vezan na potrebnu amidnu skupinu (tj. dio -C(O)-N(R1)-) putem jedne od dvije moguće veze predstavljene točkastim linijama, koje su veze povezane s prstenom A na dva različita atoma (tog prstena);
prsten A je 5-eročlani aromatski prsten koji sadrži najmanje jedan heteroatom (po mogućnosti koji sadrži najmanje jedan dušikov atom);
prsten B je 5- ili 6-eročlani prsten, koji može biti aromatski ili nearomatski, po izboru sadrži jedan do četiri heteroatoma (poželjno odabrana od dušika, kisika i sumpora);
bilo prsten A i/ili prsten B može biti po izboru supstituiran s jednim ili više supstituenata odabranih između: halo, C1-6 alkil (po izboru supstituiran s jednim ili više halo, npr. fluoro atoma) i/ili -OC1-6alkil (sam je po izboru supstituiran s jednim ili više fluoro atoma),
ili njegova farmaceutski prihvatljiva sol.
2. Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time što X1 predstavlja:
[image]
ili
[image]
u kojem su takve vezne skupine po izboru supstituirane s jednim ili više supstituenata odabranih od fluoro, CH3, CF3, -OCH3 i -OCF3.
3. Spoj za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačen time što je spirociklički dio, tj. kombinirani prsten koji sadrži Xa i Xb predstavljen kako slijedi:
[image]
[image]
[image]
[image]
[image]
4. Spoj za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva naznačen time što:
prsten A je predstavljen na sljedeći način:
[image]
[image]
i/ili
prsten B je predstavljen na sljedeći način:
[image]
[image]
[image]
[image]
[image]
pri čemu "SUB" i "Sub" predstavljaju jedan ili više mogućih supstituenata na relevantnom atomu (npr. atomu ugljika ili dušika).
5. Spoj za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što su kombinirani sustavi prstenova, tj. prsten A i prsten B predstavljeni kako slijedi:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
gdje "SUB" predstavlja jedan ili više mogućih supstituenata na biciklu (tj. na prstenu A i/ili na prstenu B) i "Sub" predstavlja mogući izborni supstituent na N atomu bicikla (u ovom kontekstu nesupstituiran značilo bi "NH").
6. Spoj za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što:
najmanje jedan od Xa i Xb predstavlja N i drugi predstavlja C(H), N ili (u slučaju Xb) O; i/ili
oba Xa i Xb ne predstavljaju C(H).
7. Spoj za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što L2 predstavlja vodik, halo, -ORf, -C(O)Rg, ili aromatsku skupinu (izborno supstituiranu s jednim ili dva supstituenta) odabrana između -OC1-6alkila (sam je po izboru supstituiran s jednim ili više fluoro atoma) ili -SF5, ili, alternativno sa halo).
8. Spoj za upotrebu prema patentnom zahtjevu 7, naznačen time što Rf predstavlja C1-6alkil ili arilnu skupinu izborno supstituiranu s C1-3alkilo, (sama je po izboru supstituirana s jednim ili više fluoro atoma, tako da tvori npr. skupinu -CF3 ) i/ili Rg predstavlja C1-3alkil (po izboru supstituiran s fluorom) ili fenil.
9. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što kada Xb je N i L2 predstavlja -S(O)2-C1-6alkil, tada predstavlja -S(O)2CF3.
10. Spoj s formulom (IA) kako je definiran u zahtjevu 1 ali naznačen time što:
L1 predstavlja -CH2-;
X1 nije prisutan ili X1 predstavlja karbocikličku aromatsku poveznu skupinu;
kada X1 predstavlja karbocikličku skupinu poveznicu on predstavlja fenilen (npr. 1,4-fenilen) na primjer:
[image]
najmanje jedan od Xa i Xb predstavlja N i drugi predstavlja C(Rc), N ili (u slučaju Xb) O;
3- do 6-eročlani prsten koji sadrži Xa i Xb spiro-cikal vezan na 4- do 6-eročlani prsten;
u jednom aspektu L2 predstavlja aromatsku skupinu (kako je ovdje definirano) po izboru supstituiranu kako je ovdje definirano, i/ili, u drugom aspektu L2 predstavlja -ORf u kojem Rf predstavlja arilnu skupinu (kako je ovdje definirano) po izboru supstituiranu kako je ovdje definirano;
kada L2 predstavlja (po izboru supstituiranu) aromatsku skupinu, to može biti fenil ili 5- ili 6-eročlana heterociklička skupina (npr. koja sadrži najmanje jedan atom dušika, tako da tvori piridil, tiazolil ili triazolil prsten; u glavnoj realizaciji heterociklička skupina je piridil), gdje su izborni supstituenti kao što je ovdje definirano;
izborni supstituenti na aromatskim L2 skupinama su odabrani između halo, C1-6 alkil, -CF3, - OC1-6 alkil i -OCF3;
kada Rf predstavlja arilnu skupinu, tada je poželjno fenil izborno supstituiran s C1-3 alkilom, sam po izboru supstituiran s fluorom);
prsten A i prsten B zajedno predstavljaju 8 ili 9-člani biciklički prsten (prsten A je 5-eročlani prsten, a prsten B može biti 5- ili 6-eročlani prsten, u kojem su oba prstena poželjno aromatska) koji sadrži najmanje jedan dušikov atom (i u glavnoj izvedbi, najmanje jedan dušikov atom koji je zajednički za oba prstena);
izborni supstituenti na prstenu A i prstenu B su halo, C1-3 alkil i -OC1-3 alkil,
ili njegova farmaceutski prihvatljiva sol.
11. Spoj s formulom (IB) kako je dolje prikazan:
[image]
pri čemu
cijeli brojevi su kao što je definirano u bilo kojem od zahtjeva 1-10, i gdje:
n1, n2, n3 i n4 neovisno predstavljaju 1;
najmanje jedan od Xa i Xb predstavlja N i drugi predstavlja CH ili N.
12. Spoj prema patentnom zahtjevu 11, sa slijedećom formulom:
[image]
naznačen time što
R1 predstavlja vodik;
L1 predstavlja -CH2-;
X1 predstavlja karbocikličku aromatsku povezujuću skupinu koja je:
1,4-fenilen:
[image]
najmanje jedan od Xa i Xb predstavlja N i drugi predstavlja CH ili N;
L2 predstavlja -S(O)2-C1-6alkil po izboru supstituiran s jednim ili više fluoro atoma;
kombinirani sustavi prstenova, tj. prsten A i prsten B predstavljeni su na sljedeći način:
[image]
i "SUB" predstavlja izborne supstituente na prstenu A i prstenu B i predstavljaju halo, C1-3 alkil i -OC1-3 alkil,
ili njegova farmaceutski prihvatljiva sol.
13. Spoj:
[image]
ili njegova farmaceutski prihvatljiva sol.
14. Spoj kako je definiran u bilo kojem od patentnih zahtjeva 10 do 13, naznačen time što se koristi kao lijek.
15. Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač i, kao aktivni sastojak, terapeutski učinkovitu količinu spoja kako je definirano u bilo kojem od patentnih zahtjeva 10-13.
16. Spoj prema bilo kojem od patentnih zahtjeva 10-13 za uporabu u liječenju tuberkuloze.
17. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 13 za proizvodnju lijeka za liječenje tuberkuloze.
18. Kombinacija (a) spoja prema bilo kojem od patentnih zahtjeva 1 do 13, i (b) jednog ili više drugih sredstava protiv tuberkuloze.
19. Proizvod naznačen time što sadrži (a) spoj prema bilo kojem od zahtjeva 1 do 13, i (b) jedno ili više drugih sredstava protiv tuberkuloze, kao kombinirani pripravak za istovremenu, odvojenu ili sekvencijalnu upotrebu u liječenju tuberkuloze.
20. Postupak za pripravu spoja s formulom (IA) prema patentnom zahtjevu 10, koji obuhvaća:
(i) reakciju spoja s formulom (II),
[image]
u kojoj su cijeli brojevi definirani u zahtjevu 1, sa spojem s formulom (III),
LG1-L2 (III)
pri čemu L2 je kao što je definirano u zahtjevu 1 (ali kada L2 nije vodik, halo ili vezan za O ili S), i LG1 je prikladna odlazeća skupina;
(ii) reakciju spoja s formulom (IV),
[image]
pri čemu su cijeli brojevi kao što je definirano u zahtjevu 1, ili njegov prikladan derivat, kao što je derivat estera karboksilne kiseline, sa spojem s formulom (V)
[image]
pri čemu su cijeli brojevi kao što je gore definirano, pod reakcijskim uvjetima amidnog sparivanja;
(iii) sparivanje spoja s formulom (VI),
[image]
pri čemu su cijeli brojevi kao što je definirano u zahtjevu 1, i LG2 predstavlja prikladnu odlazeću skupinu, sa spojem s formulom (VI),
[image]
pri čemu su cijeli brojevi kao što je definirano u zahtjevu 1;
(iv) sparivanje spoja s formulom (VIII),
[image]
pri čemu su cijeli brojevi kao što je definirano u zahtjevu 1, i LG3 predstavlja prikladnu odlazeću skupinu kako je gore opisano u odnosu na LG2 (i može naročito predstavljati klor, brom ili jod), sa spojem s formulom (IX),
LG4-L2 (IX)
pri čemu L2 je kao što je definirano u zahtjevu 1 (ali pri čemu L2 nije vodik, halo ili vezan za O ili S), i LG4 je prikladna skupina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15174936 | 2015-07-02 | ||
| EP16174718 | 2016-06-16 | ||
| EP16174713 | 2016-06-16 | ||
| PCT/EP2016/065499 WO2017001660A1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
| EP16734637.8A EP3316969B1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220339T1 true HRP20220339T1 (hr) | 2022-05-13 |
Family
ID=56289523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220339TT HRP20220339T1 (hr) | 2015-07-02 | 2016-07-01 | Antibakterijski spojevi |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US20180155341A1 (hr) |
| EP (3) | EP3316969B1 (hr) |
| JP (3) | JP7099824B2 (hr) |
| KR (2) | KR20180022826A (hr) |
| CN (3) | CN113980015A (hr) |
| AU (3) | AU2016287478B2 (hr) |
| BR (1) | BR112017028318B1 (hr) |
| CA (2) | CA2986331A1 (hr) |
| CL (1) | CL2017003404A1 (hr) |
| CO (1) | CO2017013408A2 (hr) |
| DK (1) | DK3316969T3 (hr) |
| EA (2) | EA201890204A1 (hr) |
| ES (1) | ES2914681T3 (hr) |
| HK (2) | HK1249468A1 (hr) |
| HR (1) | HRP20220339T1 (hr) |
| IL (2) | IL256379A (hr) |
| LT (1) | LT3316969T (hr) |
| MA (1) | MA42293A (hr) |
| MD (1) | MD3316969T2 (hr) |
| MX (2) | MX2017016789A (hr) |
| PE (1) | PE20180520A1 (hr) |
| PH (2) | PH12017502298B1 (hr) |
| PL (1) | PL3316969T3 (hr) |
| RS (1) | RS63201B1 (hr) |
| SI (1) | SI3316969T1 (hr) |
| UA (1) | UA125171C2 (hr) |
| WO (2) | WO2017001660A1 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| BR112017028318B1 (pt) * | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| EP3328382A4 (en) | 2015-09-17 | 2018-12-19 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| BR112018017225A2 (pt) | 2016-02-25 | 2019-01-15 | Asceneuron Sa | sal de adição de ácido, composto, métodos para preparação de um sal de adição de ácido, para tratamento de uma tauopatia e para inibição de uma glicosidase, e, forma de dosagem oral sólida. |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| HRP20230537T1 (hr) | 2016-03-16 | 2023-08-04 | Kura Oncology, Inc. | Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu |
| CA3026010A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018141984A1 (en) | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| BR112019017901A2 (pt) | 2017-03-01 | 2020-05-12 | Janssen Sciences Ireland Unlimited Company | Terapia de combinação |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| RU2680972C1 (ru) * | 2018-02-13 | 2019-03-01 | Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" | Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков |
| WO2019175737A1 (en) * | 2018-03-12 | 2019-09-19 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CN109503631A (zh) * | 2018-12-29 | 2019-03-22 | 中国医学科学院医药生物技术研究所 | 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用 |
| JP2022536043A (ja) * | 2019-05-28 | 2022-08-12 | 塩野義製薬株式会社 | シトクロムｂｃ１阻害剤とクラリスロマイシン又はアジスロマイシン及びクロファジミンを組み合わせることを特徴とするマイコバクテリア感染症治療用医薬 |
| KR102076958B1 (ko) | 2019-06-24 | 2020-02-13 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| TW202124379A (zh) | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物 |
| JP2022548247A (ja) | 2019-09-13 | 2022-11-17 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| EP4038067A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Sciences Ireland Unlimited Company | 4-quinolinone antibacterial compounds |
| US20220372033A1 (en) | 2019-09-30 | 2022-11-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| IL294363A (en) | 2019-12-27 | 2022-08-01 | Tecnimede Soc T?Cnico Medicinal Sa | Antibacterial quinolines |
| KR20230157400A (ko) | 2021-03-16 | 2023-11-16 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| EP4308579A1 (en) | 2021-03-17 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022194905A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3223626A1 (en) | 2021-06-29 | 2023-01-05 | Augusto Eugenio Pardal Filipe | Heterocyclic compounds for the treatment of tuberculosis |
| AR127483A1 (es) | 2021-10-28 | 2024-01-31 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos |
| WO2023244764A1 (en) * | 2022-06-15 | 2023-12-21 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996015130A1 (en) | 1994-11-15 | 1996-05-23 | Pharmacia + Upjohn Company | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| CA2218088A1 (en) | 1995-05-11 | 1996-11-14 | Pharmacia & Upjohn Company | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| EP1527050B1 (en) | 2002-07-25 | 2010-04-07 | Janssen Pharmaceutica N.V. | Quinoline derivatives and their use as mycobacterial inhibitors |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| CN101631786A (zh) | 2006-12-20 | 2010-01-20 | 先灵公司 | 新颖的jnk抑制剂 |
| CL2008001631A1 (es) * | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| US7666864B2 (en) | 2008-03-26 | 2010-02-23 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazole-substituted phenyl oxazolidinones |
| EP2385371B1 (en) | 2008-09-22 | 2014-10-22 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| US20120040951A1 (en) | 2008-12-30 | 2012-02-16 | Claudio Chuaqui | Heteroaryl compounds useful as raf kinase inhibitors |
| CN110483499A (zh) | 2009-11-05 | 2019-11-22 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| PL2547678T3 (pl) * | 2010-03-18 | 2016-10-31 | Związki przeciwzapalne | |
| US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
| AU2012302176A1 (en) | 2011-09-01 | 2014-04-17 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| ES2761332T3 (es) | 2011-09-01 | 2020-05-19 | Novartis Ag | Compuestos y composiciones como inhibidores de la cinasa c-kit |
| US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| KR102178590B1 (ko) * | 2012-07-18 | 2020-11-13 | 유니버시티 오브 노트르 담 듀락 | 5,5-헤테로방향족 항-감염 화합물 |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| CN109575018A (zh) * | 2013-08-02 | 2019-04-05 | 韩国巴斯德研究所 | 一种抗感染化合物 |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| US10080749B2 (en) | 2014-11-03 | 2018-09-25 | The Regents Of The University Of California | Multi-drug therapies for tuberculosis treatment |
| BR112017028318B1 (pt) * | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| CA3026010A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| BR112018075939A2 (pt) | 2016-06-16 | 2019-04-09 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| BR112019017901A2 (pt) | 2017-03-01 | 2020-05-12 | Janssen Sciences Ireland Unlimited Company | Terapia de combinação |
-
2016
- 2016-07-01 BR BR112017028318-2A patent/BR112017028318B1/pt active IP Right Grant
- 2016-07-01 HR HRP20220339TT patent/HRP20220339T1/hr unknown
- 2016-07-01 MX MX2017016789A patent/MX2017016789A/es unknown
- 2016-07-01 CA CA2986331A patent/CA2986331A1/en not_active Abandoned
- 2016-07-01 PL PL16734637T patent/PL3316969T3/pl unknown
- 2016-07-01 KR KR1020187001923A patent/KR20180022826A/ko not_active Application Discontinuation
- 2016-07-01 US US15/736,524 patent/US20180155341A1/en not_active Abandoned
- 2016-07-01 JP JP2017567655A patent/JP7099824B2/ja active Active
- 2016-07-01 WO PCT/EP2016/065499 patent/WO2017001660A1/en active Application Filing
- 2016-07-01 MA MA042293A patent/MA42293A/fr unknown
- 2016-07-01 PE PE2017002738A patent/PE20180520A1/es unknown
- 2016-07-01 AU AU2016287478A patent/AU2016287478B2/en not_active Expired - Fee Related
- 2016-07-01 CN CN202111173668.2A patent/CN113980015A/zh active Pending
- 2016-07-01 UA UAA201800904A patent/UA125171C2/uk unknown
- 2016-07-01 CA CA2986326A patent/CA2986326A1/en active Pending
- 2016-07-01 RS RS20220464A patent/RS63201B1/sr unknown
- 2016-07-01 DK DK16734637.8T patent/DK3316969T3/da active
- 2016-07-01 AU AU2016287477A patent/AU2016287477B2/en active Active
- 2016-07-01 KR KR1020187002072A patent/KR20180022833A/ko not_active Application Discontinuation
- 2016-07-01 EP EP16734637.8A patent/EP3316969B1/en active Active
- 2016-07-01 JP JP2017567289A patent/JP2018519302A/ja active Pending
- 2016-07-01 SI SI201631501T patent/SI3316969T1/sl unknown
- 2016-07-01 MD MDE20180478T patent/MD3316969T2/ro unknown
- 2016-07-01 ES ES16734637T patent/ES2914681T3/es active Active
- 2016-07-01 LT LTEPPCT/EP2016/065499T patent/LT3316969T/lt unknown
- 2016-07-01 EP EP22158386.7A patent/EP4074378A1/en active Pending
- 2016-07-01 EA EA201890204A patent/EA201890204A1/ru unknown
- 2016-07-01 US US15/736,375 patent/US10364232B2/en active Active
- 2016-07-01 MX MX2017016788A patent/MX2017016788A/es unknown
- 2016-07-01 CN CN201680038644.7A patent/CN108235704B/zh active Active
- 2016-07-01 WO PCT/EP2016/065503 patent/WO2017001661A1/en active Application Filing
- 2016-07-01 EP EP16733105.7A patent/EP3316968A1/en not_active Ceased
- 2016-07-01 CN CN201680038659.3A patent/CN107708809A/zh active Pending
- 2016-07-01 EA EA201890201A patent/EA201890201A1/ru unknown
-
2017
- 2017-12-13 PH PH12017502298A patent/PH12017502298B1/en unknown
- 2017-12-13 PH PH12017502297A patent/PH12017502297A1/en unknown
- 2017-12-18 IL IL256379A patent/IL256379A/en unknown
- 2017-12-18 IL IL256391A patent/IL256391B/en active IP Right Grant
- 2017-12-26 CO CONC2017/0013408A patent/CO2017013408A2/es unknown
- 2017-12-27 CL CL2017003404A patent/CL2017003404A1/es unknown
-
2018
- 2018-07-13 HK HK18109081.1A patent/HK1249468A1/zh unknown
- 2018-10-25 HK HK18113658.6A patent/HK1254677A1/zh unknown
-
2019
- 2019-07-02 US US16/460,334 patent/US20190330189A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/848,337 patent/US11180472B2/en active Active
-
2021
- 2021-09-17 US US17/477,970 patent/US11866419B2/en active Active
- 2021-11-30 JP JP2021194493A patent/JP2022043078A/ja active Pending
-
2022
- 2022-01-20 AU AU2022200385A patent/AU2022200385A1/en active Pending
-
2023
- 2023-11-29 US US18/523,171 patent/US20240132470A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220339T1 (hr) | Antibakterijski spojevi | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| EP4295841A3 (en) | Sulfur (vi) fluoride compounds and their use in click-reaction | |
| EA201892734A1 (ru) | ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA | |
| MX2011008501A (es) | Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide. | |
| MX2014001665A (es) | Derivado heterociclico y farmaceutico. | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| MEP43308A (hr) | Derivati cikloalkilamino kisjeline i njihove farmaceutske kompozicije | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| PH12019502562A1 (en) | N-substituted indole derivatives | |
| CY1124245T1 (el) | Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4 | |
| EA202091641A1 (ru) | 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| PH12020550265A1 (en) | Benzimidazole derivatives and their uses | |
| EA201691934A1 (ru) | Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1 | |
| PE20220964A1 (es) | Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| RU2011119450A (ru) | Содержащее конденсированную кольцевую структуру производное и его применение в медицине | |
| EA202092955A1 (ru) | Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза | |
| TW201612188A (en) | The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor |